Categories: Blood diseases, Bone diseases, Rare diseases

Aliases & Classifications for Osteonecrosis

Summaries for Osteonecrosis

MedlinePlus : 43 Osteonecrosis is a disease caused by reduced blood flow to bones in the joints. In people with healthy bones, new bone is always replacing old bone. In osteonecrosis, the lack of blood causes the bone to break down faster than the body can make enough new bone. The bone starts to die and may break down. You can have osteonecrosis in one or several bones. It is most common in the upper leg. Other common sites are your upper arm and your knees, shoulders and ankles. The disease can affect men and women of any age, but it usually strikes in your thirties, forties or fifties. At first, you might not have any symptoms. As the disease gets worse, you will probably have joint pain that becomes more severe. You may not be able to bend or move the affected joint very well. No one is sure what causes the disease. Risk factors include Long-term steroid treatment Alcohol abuse Joint injuries Having certain diseases, including arthritis and cancer Doctors use imaging tests and other tests to diagnose osteonecrosis. Treatments include medicines, using crutches, limiting activities that put weight on the affected joints, electrical stimulation and surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Osteonecrosis, also known as bone necrosis, is related to osteonecrosis of the jaw and legg-calve-perthes disease, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Osteonecrosis is BMP2 (Bone Morphogenetic Protein 2), and among its related pathways/superpathways are Selenium Micronutrient Network and Formation of Fibrin Clot (Clotting Cascade). The drugs Zoledronic Acid and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and breast, and related phenotypes are growth/size/body region and cardiovascular system

Disease Ontology : 12 An ischemic bone disease that results in necrosis located in bone.

Wikipedia : 75 Avascular necrosis (AVN), also called osteonecrosis or bone infarction, is death of bone tissue due to... more...

Related Diseases for Osteonecrosis

Diseases related to Osteonecrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 673)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis of the jaw 34.4 VEGFA FDPS CYP2C8
2 legg-calve-perthes disease 32.9 SERPINE1 SERPINC1 COL2A1
3 thrombophilia 31.2 SERPINE1 SERPINC1 MTHFR F2
4 sickle cell anemia 31.1 TNF MTHFR F2
5 mucositis 31.0 VEGFA MTHFR ABCB1
6 thrombophilia due to thrombin defect 30.9 SERPINE1 SERPINC1 MTHFR F2
7 antiphospholipid syndrome 30.9 SERPINC1 MTHFR F2
8 disseminated intravascular coagulation 30.8 SERPINE1 SERPINC1 F2
9 endosteal hyperostosis, autosomal dominant 30.8 TNFSF11 TNFRSF11B BMP2
10 protein s deficiency 30.8 SERPINC1 MTHFR F2
11 protein c deficiency 30.7 SERPINC1 MTHFR F2
12 pulmonary embolism 30.7 SERPINE1 SERPINC1 MTHFR F2
13 purpura 30.6 TNF SERPINC1 F2
14 paget's disease of bone 30.5 TNFSF11 TNFRSF11B BGLAP
15 osteomyelitis 30.5 TNFSF11 TNF BMP2 ACP5
16 synovitis 30.5 TNFSF11 TNFRSF11B TNF
17 arthropathy 30.4 TNFSF11 TNFRSF11B TNF
18 myeloma, multiple 30.4 VEGFA TNFSF11 TNFRSF11B TNF DKK1 ABCB1
19 homocysteinemia 30.4 SERPINC1 MTHFR F2
20 antithrombin iii deficiency 30.2 SERPINC1 MTHFR F2
21 thrombophlebitis 30.2 SERPINE1 SERPINC1 MTHFR F2
22 thrombosis 30.2 SERPINE1 SERPINC1 MTHFR F2
23 giant cell tumor 30.1 TNFSF11 TNFRSF11B BGLAP
24 kummell's disease 30.0 TNFSF11 TNFRSF11B DKK1
25 intracranial thrombosis 30.0 SERPINC1 PLG MTHFR
26 hellp syndrome 30.0 SERPINE1 SERPINC1 MTHFR F2
27 peripheral vascular disease 29.9 VEGFA SERPINE1 SERPINC1 F2
28 renal osteodystrophy 29.9 TNFRSF11B PTH BGLAP
29 cerebrovascular disease 29.9 TNF SERPINE1 MTHFR F2
30 thrombophilia due to activated protein c resistance 29.9 SERPINE1 SERPINC1 PLG MTHFR F2
31 villonodular synovitis 29.9 TNFSF11 ACP5
32 periodontitis, chronic 29.8 TNFSF11 TNFRSF11B
33 periodontitis 29.8 TNFSF11 TNFRSF11B TNF RUNX2 BGLAP
34 eclampsia 29.8 TNF SERPINC1 MTHFR F2
35 pre-eclampsia 29.7 VEGFA SERPINE1 SERPINC1 MTHFR F2
36 alveolar periostitis 29.7 RUNX2 PLG BGLAP
37 stroke, ischemic 29.6 SERPINE1 SERPINC1 PLG MTHFR F2
38 ankylosis 29.5 TNFRSF11B RUNX2 BMP2 BGLAP
39 root resorption 29.5 TNFSF11 TNFRSF11B RUNX2
40 osteoporosis, juvenile 29.2 PTH DKK1 BGLAP
41 periapical periodontitis 29.2 TNFSF11 TNFRSF11B TNF ACP5
42 hyperparathyroidism 29.1 TNFRSF11B PTH BGLAP ACP5
43 rheumatoid arthritis 29.0 VEGFA TNFSF11 TNFRSF11B TNF ACP5
44 vascular disease 29.0 VEGFA TNFRSF11B TNF SERPINE1 SERPINC1 PLG
45 bone inflammation disease 28.8 TNFSF11 TNFRSF11B TNF COL2A1 BGLAP ACP5
46 bone resorption disease 27.9 TNFSF11 TNFRSF11B RUNX2 PTH DKK1 BMP2
47 bone disease 27.4 TNFSF11 TNFRSF11B TNF RUNX2 PTH DKK1
48 glucocorticoid-induced osteoporosis 27.0 TNFSF11 TNFRSF11B RUNX2 PTH DKK1 BMP2
49 osteoporosis 26.8 TNFSF11 TNFRSF11B TNF RUNX2 PTH FDPS
50 dysbaric osteonecrosis 12.6

Graphical network of the top 20 diseases related to Osteonecrosis:

Diseases related to Osteonecrosis

Symptoms & Phenotypes for Osteonecrosis

UMLS symptoms related to Osteonecrosis:

back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Osteonecrosis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.37 ABCB1 BMP2 COL2A1 DKK1 F2 MTHFR
2 cardiovascular system MP:0005385 10.34 ABCB1 BMP2 COL2A1 F2 PLG PTH
3 homeostasis/metabolism MP:0005376 10.34 ABCB1 BMP2 COL2A1 DKK1 F2 MTHFR
4 hematopoietic system MP:0005397 10.29 ABCB1 BMP2 F2 PLG PTH RUNX2
5 immune system MP:0005387 10.29 ABCB1 BMP2 COL2A1 F2 PLG PTH
6 mortality/aging MP:0010768 10.24 ABCB1 BMP2 COL2A1 DKK1 F2 MTHFR
7 craniofacial MP:0005382 10.2 BMP2 COL2A1 DKK1 PTH RUNX2 TNF
8 digestive/alimentary MP:0005381 10.14 ABCB1 BMP2 COL2A1 F2 PLG RUNX2
9 limbs/digits/tail MP:0005371 10.13 BMP2 COL2A1 DKK1 MTHFR PTH RUNX2
10 integument MP:0010771 10.06 F2 MTHFR PLG RUNX2 SERPINE1 TNF
11 liver/biliary system MP:0005370 10.06 ABCB1 COL2A1 MTHFR PLG RUNX2 SERPINC1
12 nervous system MP:0003631 10.06 ABCB1 BMP2 COL2A1 DKK1 F2 MTHFR
13 reproductive system MP:0005389 9.96 ABCB1 BMP2 F2 MTHFR PLG RUNX2
14 respiratory system MP:0005388 9.81 COL2A1 DKK1 F2 PLG RUNX2 SERPINE1
15 skeleton MP:0005390 9.7 BMP2 COL2A1 DKK1 F2 MTHFR PTH
16 vision/eye MP:0005391 9.28 COL2A1 DKK1 MTHFR PLG RUNX2 SERPINC1

Drugs & Therapeutics for Osteonecrosis

Drugs for Osteonecrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Zoledronic Acid Approved Phase 4 118072-93-8 68740
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
8 Anesthetics Phase 4
9 Neuroprotective Agents Phase 4
10 Methylprednisolone Acetate Phase 4
11 Prednisolone acetate Phase 4
12 Parenteral Nutrition Solutions Phase 4
13 Ferrosoferric Oxide Phase 4
14 Adjuvants, Immunologic Phase 4
15 Viscosupplements Phase 4
Tranexamic Acid Approved Phase 3 1197-18-8 5526
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
Calcium carbonate Approved, Investigational Phase 3 471-34-1
Denosumab Approved Phase 3 615258-40-7
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
Allopurinol Approved Phase 3 315-30-0 2094
rituximab Approved Phase 3 174722-31-7 10201696
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
Mercaptopurine Approved Phase 3 50-44-2 667490
Pegaspargase Approved, Investigational Phase 3 130167-69-0
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
leucovorin Approved Phase 3 58-05-9 143 6006
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Daunorubicin Approved Phase 3 20830-81-3 30323
Thioguanine Approved Phase 3 154-42-7 2723601
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
Etoposide Approved Phase 3 33419-42-0 36462
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
Ichthammol Approved Phase 3 8029-68-3
Dasatinib Approved, Investigational Phase 3 302962-49-8 3062316
Etoricoxib Approved, Investigational Phase 3 202409-33-4 123619
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3 67-97-0 6221 5280795
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793

Interventional clinical trials:

(show top 50) (show all 200)
# Name Status NCT ID Phase Drugs
1 Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis Unknown status NCT00265252 Phase 4 Alendronate
2 A Phase IV, Multi-center, Open Label, Single Arm Clinical Trial to Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients Unknown status NCT00912938 Phase 4 zoledronic acid
3 Randomized, Prospective, Multi-center, Comparison Study of 3-4-screws-internal Fixation With Multi-screw-system Targon FN for Femoral Neck Fracture Unknown status NCT00829725 Phase 4
4 Comparison of Ceramic-on-Ceramic and Ceramic-on-Highly-Cross-Linked Polyethylene Bearings in Primary Cementless Total Hip Arthroplasty in the Same Patients Completed NCT01806766 Phase 4
5 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
6 A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients Completed NCT01345097 Phase 4
7 Advances in the Management of Mandibular Osteoradionecrosis: Pentoxifylline and Tocopherol as Medical Treatment Completed NCT02368457 Phase 4 Pentoxifylline and Tocopherol
8 Comparison of the Outcomes of Ultra-Short Anatomic and Conventional Cementless Stems in Patients Younger Than Fifty-Five Years Old Completed NCT02338596 Phase 4
9 Prospective Evaluation of Perioperative Steroid Dosing on Postsurgical Edema in Orthognathic Surgery Recruiting NCT03190642 Phase 4 Methylprednisolone
10 Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI Recruiting NCT02893293 Phase 4 Ferumoxytol-enhanced magnetic resonance imaging
11 The Efficacy of Ultrasound Guided Glenohumeral Joint Injections of Platelet Rich Plasma (PRP) Versus Hyaluronic Acid (HA) in the Treatment of Glenohumeral Osteoarthritis: a Randomized, Double-blind Control Trial Recruiting NCT02984228 Phase 4 Hyaluronic Acid
12 Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial Recruiting NCT02286830 Phase 4 Zoledronic acid
13 A Prospective, Single-center, Non-randomized, Consecutive Series Clinical Study Comparing the Functional Differences Between a Standard Posterior Stabilized Total Knee Replacement and a High-flexion Posterior Stabilized Total Knee Replacement Withdrawn NCT00808613 Phase 4
14 Control Study of Implantation of Enriched Bone Marrow Cells for the Treatment of Avascular Necrosis of Femoral Head Unknown status NCT01613612 Phase 2, Phase 3
15 Use of Tranexamic Acid(TNA) in Preventing Blood Loss During and After Total Hip Arthroplasty Unknown status NCT02587845 Phase 3 Tranexamic Acid (IV);Tranexamic Acid (Topical)
16 Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases Unknown status NCT00326820 Phase 3 ibandronate sodium;zoledronic acid;Zolendronic Acid
17 Metabolic, Endocrine, and Central Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis Unknown status NCT03040531 Phase 2, Phase 3 Alendronate Oral Tablet
18 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
19 Multi-center Clinical Trial of the Application of Ixmyelocel-T in the Treatment of Osteonecrosis of the Femoral Head Completed NCT00505219 Phase 3
20 Multicenter, Open-labeled, Randomized Clinical Trial to Determine the Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head Completed NCT00939900 Phase 3 zoledronic acid (aclasta)
21 Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial Completed NCT00532220 Phase 3 Ibandronate IV;Placebo
22 A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer Completed NCT00869206 Phase 3 zoledronic acid
23 Preventing Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone Completed NCT01924286 Phase 3 Prednisone;Placebo
24 Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss in Non-Hodgkin's Lymphoma Patients Receiving Chemotherapy Completed NCT00352846 Phase 3 Zoledronic Acid;Vitamin D;Calcium Carbonate
25 Aspirin (Acetylsalicylic Acid) in the Prevention of Collapse of the Femoral Head in Early-stage Non-traumatic Osteonecrosis: a Two-year Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study Recruiting NCT03405974 Phase 3 Aspirin;Placebo
26 Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment Recruiting NCT03040778 Phase 3 Pentoxifylline;Placebo;Tocopherol
27 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial Recruiting NCT02051218 Phase 3 Denosumab (reduced dosing);Denosumab (standard dosing)
28 A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL Recruiting NCT03150693 Phase 3 Allopurinol;Cytarabine;Daunorubicin Hydrochloride;Vincristine Sulfate;Dexamethasone;Pegylated L-Asparaginase;Methotrexate;Cyclophosphamide;Mercaptopurine;Doxorubicin;Thioguanine
29 Combined Treatment of Early and Advanced Osteonecrosis of the Femoral Head With Core Decompression and Grafting With Demineralized Bone Matrix (DBM) or Homologous Lyophilized Bone Chips (LBC) Together With Platelet-rich-fibrin (PRF) and Concentrated Bone Marrow (CBM) Active, not recruiting NCT01892514 Phase 3
30 A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations Active, not recruiting NCT02883049 Phase 3 Clofarabine;Cyclophosphamide;Cytarabine;Dasatinib;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
31 Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw: a Multicenter, Randomized, Clinical Trial Not yet recruiting NCT03390777 Phase 2, Phase 3
32 Phase 3, Pivotal, Multicentre, Randomised, Double-blind Controlled Study to Evaluate the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Early Stage Non Traumatic Osteonecrosis of the Femoral Head Terminated NCT01529008 Phase 3 Core decompression/PREOB® implantation;Core decompression/placebo implantation
33 Double Blind Randomized Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis Stage 1 and 2 Terminated NCT02114489 Phase 3 ibandronate;Placebo
34 Efficacy and Safety of Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder Terminated NCT00876317 Phase 3 Etoricoxib 60 mg;Etoricoxib 90 mg
35 Evaluation of Safety and Performance of Macroporous Biphasic Calcium Phosphate Granules Combined With Cellulosic-Derived Gel, in Filling Bones Gap After Aseptic Osteonecrosis Biopsy of Femur Head. Unknown status NCT00289575 Phase 2
36 The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC) Unknown status NCT03180463 Phase 1, Phase 2 Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)
37 A Randomised Controlled Trial of Bisphosphonate Therapy in Osteonecrosis of the Hip Unknown status NCT00781261 Phase 2 Zoledronic Acid;Placebo
38 Hyperbaric Oxygen Treatment of Mandibular Osteoradionecrosis. A Randomized Clinical Study Unknown status NCT00760682 Phase 2
39 PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells Completed NCT01700920 Phase 2
40 Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD- A Phase I/II Clinical Trial Completed NCT02824653 Phase 1, Phase 2
41 Treatment of Osteonecrosis of the Femoral Head by Implantation of Preosteoblastic Cells: a Randomized, Controlled, Single Blind Pilot Study Completed NCT02890537 Phase 2 Core decompression/PREOB® implantation;Core decompression/BMC implantation
42 Effect of Hydroxyurea on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia Completed NCT00001197 Phase 2 Hydroxyurea
43 Effect of Cycle Ergometer in the Rehabilitation of Elderly Patients With Total Hip Arthroplasty: Randomized Controlled Trial Completed NCT01622465 Phase 2
44 Phase II Clinical Trial of Tissue Engineering Based on the Use of Mononuclear Cells From Autologous Bone Marrow Seeded on Porous Tricalcium Phosphate Biomaterial in Patients With Pseudoarthrosis Completed NCT01813188 Phase 2
45 Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone Completed NCT00760370 Phase 2 Zoledronic Acid
46 Treatment of Osteoporosis With Unfocused Extracorporeal Shock Wave Therapy: Pilot Study Completed NCT02630381 Phase 2
47 Pilot Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI Completed NCT01336803 Phase 2 Feraheme
48 Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease Completed NCT02321280 Phase 1, Phase 2 Denosumab
49 Multicentered, Randomized Study of Safety and Efficacy of Whole-body Vibration as add-on to Standard Pharmacological Treatment of Osteoporosis in Post-menopausal Women Completed NCT01415050 Phase 2
50 Transcranial Direct Current Stimulation Associated With Peripheral Electrical Stimulation for Pain Control in Individuals With Sickle Cell Disease Recruiting NCT02813629 Phase 2

Search NIH Clinical Center for Osteonecrosis

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteonecrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteonecrosis:
JACC, cultured cartilage for chondral lesion
PREOB, autologous osteoblasts for bone disorders
Embryonic/Adult Cultured Cells Related to Osteonecrosis:
Cultured cartilage (JACC) PMIDs: 19393556 10738867 16226641 12043781 16233853 19802670 10679677 11284883 16233778

Cochrane evidence based reviews: osteonecrosis

Genetic Tests for Osteonecrosis

Genetic tests related to Osteonecrosis:

# Genetic test Affiliating Genes
1 Aseptic Necrosis 29

Anatomical Context for Osteonecrosis

MalaCards organs/tissues related to Osteonecrosis:

Bone, Bone Marrow, Breast, Testes, Endothelial, Prostate, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Osteonecrosis:


Publications for Osteonecrosis

Articles related to Osteonecrosis:

(show top 50) (show all 10409)
# Title Authors PMID Year
Risk profile for antiangiogenic agent-related osteonecrosis of the jaws. 38 17
31340246 2019
IGF-1 polymorphisms modulate the susceptibility to osteonecrosis of the femoral head among Chinese Han population. 38 17
31169709 2019
Pain catastrophizing, anxiety, and depression in hip pathology. 17
31256659 2019
Early diagnosis of jaw osteomyelitis by easy digitalized panoramic analysis. 38
30800645 2019
Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw. 38
31403036 2019
Association between NOS3 polymorphisms and osteonecrosis of the femoral head. 38
31007072 2019
Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication). 38
30815046 2019
Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (1), role of imaging in drug-related osteonecrosis of the jaw: An up-to-date review (secondary publication). 38
30705708 2019
Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw. 38
30949253 2019
Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ). 38
31193410 2019
Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (6), assessment of mandibular metabolism due to long-term administration of an anti-resorptive agent by bone scintigraphy (secondary publication). 38
30815045 2019
☆Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (5), utility of bone scintigraphy and 18F-FDG PET/CT in early detection and risk assessment of medication-related osteonecrosis of the jaw (secondary publication). 38
30956739 2019
Metal trabecular bone reconstruction system better improves clinical efficacy and biomechanical repair of osteonecrosis of the femoral head than free vascularized fibular graft: A case-control study. 38
31127611 2019
Imaging modalities for drug-related osteonecrosis of the jaw (2), Overview of the position paper on medication-related osteonecrosis of the jaw and the current status of the MRONJ in Japan. 38
30949254 2019
Osimertinib and jaw osteonecrosis? A case report. 38
31081942 2019
Author's Reply to: Osimertinib and jaw osteonecrosis? A case report. 38
31074838 2019
Evaluation of Heat Generation in Unidirectional Versus Oscillatory Modes During K-Wire Insertion in Bone. 38
31081555 2019
Spica MRI predictors for epiphyseal osteonecrosis after closed reduction treatment of dysplasia of the hip. 38
30807510 2019
Everolimus-induced osteonecrosis of the jaw in the absence of bisphosphonates: a case report. 38
31202510 2019
The unstable slipped capital femoral epiphysis: does the rate of osteonecrosis really depend on the timing of surgery and surgical technique? 38
30768578 2019
Osteonecrosis of the External Auditory Canal Associated With Oral Sorafenib Therapy: Sorafenib and Temporal Bone Osteonecrosis. 38
31356482 2019
Spontaneous Spinal Epidural Hematoma with Lumbar Facet Joint Destruction Mimicking Pigmented Villonodular Synovitis. 38
31254704 2019
Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment. 38
31125092 2019
Long-term outcome of cemented total hip arthroplasty with the Charnley-type femoral stem made of titanium alloy. 38
31422864 2019
Increased perfusion in dynamic gadolinium-enhanced MRI correlates with areas of bone repair and of bone necrosis in patients with Kienböck's disease. 38
30556360 2019
The MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) 2.0 Knee Score and Atlas. 38
31422674 2019
Bibliometric Analysis of Medication-Related Osteonecrosis of the Jaw: High Citation Rates but Low Evidence. 38
31108060 2019
Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. 38
31378564 2019
Diagnostic accuracy of digital radiography for the diagnosis of osteonecrosis of the femoral head, revisited. 38
30326729 2019
Maxillar osteonecrosis related to denosumab. Evaluation of nine cases. 38
31427154 2019
Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. 38
31410544 2019
Treatment of medication-related osteonecrosis of the jaw around dental implant with a once-weekly teriparatide: A case report and literature review. 38
31429640 2019
Retrospective Long-Term Follow-Up Survival Analysis of the Management of Osteonecrosis of the Femoral Head With Pedicled Vascularized Iliac Bone Graft Transfer. 38
31031157 2019
Volume of hip synovitis detected on contrast-enhanced magnetic resonance imaging is associated with disease severity after collapse in osteonecrosis of the femoral head. 38
30697641 2019
The Use of the Proximal Hamate as an Autograft for Proximal Pole Scaphoid Fractures: Clinical Outcomes and Biomechanical Implications. 38
31178087 2019
Increased bone marrow-specific adipogenesis by clofazimine causes impaired fracture healing, osteopenia and osteonecrosis without extra-skeletal effects in rats. 38
31393584 2019
Focused extra-corporeal shockwave treatment during early stage of osteonecrosis of femoral head. 38
31306227 2019
Significant association between RETN genetic polymorphisms and alcohol-induced osteonecrosis of femoral head. 38
31207150 2019
Hypertension is a modifiable risk-factor for osteonecrosis in acute lymphoblastic leukemia. 38
31409674 2019
Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case-control study. 38
30929994 2019
CORR Insights®: CORR® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor- γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation. 38
31107340 2019
CORR® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor-γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation. 38
31135556 2019
Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis. 38
31256803 2019
BMSCs-derived Exosomes Carrying MicroRNA-122-5p Promote Progression of Osteoblasts in Osteonecrosis of the Femoral Head. 38
31387936 2019
Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis. 38
31373407 2019
Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review. 38
30406491 2019
Osteonecrosis of the femoral head with subchondral collapse. 38
31385795 2019
[Differential diagnoses of osteonecrosis of large joints]. 38
31317211 2019
Medication-Related Osteonecrosis of the Jaws. 38
31425596 2019
Costs of Oral Complications of Cancer Therapies: Estimates and a Blueprint for Future Study. 38
31425598 2019

Variations for Osteonecrosis

Expression for Osteonecrosis

Search GEO for disease gene expression data for Osteonecrosis.

Pathways for Osteonecrosis

Pathways related to Osteonecrosis according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
11 11.37 VEGFA TNFSF11 DKK1
14 10.77 F2 BGLAP
15 10.76 CYP2C8 ABCB1
17 10.7 TNFSF11 TNFRSF11B ACP5
18 10.68 SERPINE1 PLG
19 10.67 DKK1 BMP2

GO Terms for Osteonecrosis

Cellular components related to Osteonecrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.77 VEGFA TNF PLG BMP2 ABCB1
2 extracellular region GO:0005576 9.77 VEGFA TNFSF11 TNFRSF11B TNF SERPINE1 SERPINC1
3 endoplasmic reticulum lumen GO:0005788 9.62 SERPINC1 F2 COL2A1 BGLAP
4 collagen-containing extracellular matrix GO:0062023 9.56 SERPINE1 SERPINC1 PLG COL2A1
5 extracellular space GO:0005615 9.44 VEGFA TNFSF11 TNFRSF11B TNF SERPINE1 SERPINC1
6 platelet alpha granule lumen GO:0031093 9.33 VEGFA SERPINE1 PLG

Biological processes related to Osteonecrosis according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.88 TNFRSF11B TNF SERPINE1 COL2A1
2 response to drug GO:0042493 9.85 TNFRSF11B PTH MTHFR BGLAP ABCB1
3 positive regulation of gene expression GO:0010628 9.85 VEGFA TNFSF11 TNF RUNX2 DKK1 BMP2
4 positive regulation of protein phosphorylation GO:0001934 9.83 VEGFA TNF F2 BMP2
5 osteoblast differentiation GO:0001649 9.81 RUNX2 BMP2 BGLAP
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.78 TNFSF11 TNFRSF11B TNF
7 positive regulation of MAP kinase activity GO:0043406 9.75 VEGFA TNFSF11 TNF
8 hemostasis GO:0007599 9.72 SERPINC1 PLG F2
9 bone development GO:0060348 9.71 TNFSF11 COL2A1 BGLAP
10 chondrocyte differentiation GO:0002062 9.69 RUNX2 COL2A1 BMP2
11 cellular response to BMP stimulus GO:0071773 9.65 RUNX2 COL2A1 BMP2
12 positive regulation of ossification GO:0045778 9.63 PTH BMP2
13 response to inorganic substance GO:0010035 9.63 TNFRSF11B BGLAP
14 skeletal system development GO:0001501 9.63 TNFRSF11B RUNX2 PTH COL2A1 BMP2 BGLAP
15 regulation of blood coagulation GO:0030193 9.62 SERPINC1 F2
16 positive regulation of blood coagulation GO:0030194 9.62 SERPINE1 F2
17 negative regulation of cardiac muscle cell differentiation GO:2000726 9.61 DKK1 BMP2
18 bone resorption GO:0045453 9.61 TNFSF11 PTH ACP5
19 proteoglycan metabolic process GO:0006029 9.6 COL2A1 BMP2
20 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.59 RUNX2 BMP2
21 fibrinolysis GO:0042730 9.58 SERPINE1 PLG F2
22 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.56 RUNX2 BMP2
23 regulation of osteoclast differentiation GO:0045670 9.5 TNFSF11 TNF BGLAP
24 bone mineralization GO:0030282 9.49 BMP2 BGLAP
25 negative regulation of fibrinolysis GO:0051918 9.43 SERPINE1 PLG F2
26 ossification GO:0001503 9.43 TNFSF11 RUNX2 COL2A1 BMP2 BGLAP ACP5
27 regulation of signaling receptor activity GO:0010469 8.32 SERPINE1
28 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 VEGFA TNFSF11 TNF SERPINE1 RUNX2 PTH

Molecular functions related to Osteonecrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.43 TNF SERPINE1 SERPINC1
2 growth factor activity GO:0008083 9.26 VEGFA F2 DKK1 BMP2
3 co-receptor binding GO:0039706 9.16 DKK1 BMP2
4 cytokine activity GO:0005125 9.02 VEGFA TNFSF11 TNFRSF11B TNF BMP2

Sources for Osteonecrosis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....